Drugs / ALVAC-HIV MN120TMG (vCP205)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000946 | ? → Mar 2001 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC-HIV MN120TMG (vCP205) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000946 ↗ |
| Modality | Vaccine | “The three experimental HIV vaccines used in this study are called ALVAC-HIV vCP205, HIV-1 SF-2 p24, and HIV-1 SF-2 rgp120.” NCT00000946 ↗ |